Hecht Beth’s Steady Xeris Biopharma Sell‑Off Signals Strategic Realignment, Not Crisis
Hecht Beth’s steady insider sales at Xeris Biopharma signal a strategic realignment and possible undervaluation—watch how pipeline prospects may drive a rally or decline.
- XERIS BIOPHARMA HOLDINGS INC
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read






